Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children
Status:
Withdrawn
Trial end date:
2018-09-04
Target enrollment:
Participant gender:
Summary
Children treated by bone marrow transplantation (BMT) experience bone toxicity. Those bone
damages are caused by both a decrease of bone formation and an increase of bone destruction
after BMT.For long term survivors, bone complications are major determinants of impaired
quality of life. No standard treatment currently exists to prevent those bone injuries.
Denosumab is a treatment which specifically blocks bone destruction for 4 to 6 months in
adults. This trial will study whether it is safe to prescribe Denosumab to children after BMT
in the aim of preventing bone complications.